Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer Cang S; Ma Y; Liu DJ Hematol Oncol 2009[Jun]; 2 (ä): 22DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.|Animals[MESH]|Antineoplastic Agents/pharmacology/therapeutic use[MESH]|Epigenesis, Genetic/*drug effects[MESH]|Gene Expression Regulation, Neoplastic/drug effects[MESH]|Gene Targeting/methods[MESH]|Histone Deacetylase Inhibitors/chemistry/pharmacology/*therapeutic use[MESH]|Humans[MESH]|Hydroxamic Acids/pharmacology/therapeutic use[MESH]|Medical Oncology/*trends[MESH]|Neoplasms/*drug therapy/genetics[MESH]|Vorinostat[MESH] |